24 results about "Allotransplantation" patented technology

A method for sequencing can be used to monitor a recipient of an allograft. A sample comprising nucleic acid molecules can be provided from the recipient of the allograft. A plurality of nucleic acid molecules can be isolated from the sample and amplified. The plurality of nucleic acid molecules can be subjected to one or more amplification reactions using a plurality of primers to generate a plurality of DNA molecules. The plurality of primers can target at least 100 independent polymorphisms. The DNA molecules, or derivatives thereof, can be sequenced. The method may not require genotyping of the recipient.

The present invention provides a human T cell lacking human leukocyte antigen (HLA) class I molecule and containing an exogenous ST6GALNAC6 gene, which has the following characteristics (a) and / or (b):(a) CD62L-positive and CD45RA-positive(b) a total ATP production rate of a human T cell-containing cell population of 400 pmol / min / 105 cells or more and a mitochondrial spare respiratory capacity of 40 pmol / min / 105 cells or more, 5-6 days after the application of T cell proliferation stimulation to the cell population. According to the present invention, a low-immunogenic human T cell that can remain stably in the body for a long period of time after transplantation is provided, and the development of a versatile CAR-T cell or TCR-T cell for allotransplantation becomes possible by using the human T cell.

Embodiments described herein relate to restorative solutions for segmental peripheral nerve (PN) defects using allografted PNs for stimulating PN repair. More specifically, embodiments described herein provide for localized immunosuppression (LIS) surrounding PN allografts as an alternative to systemically suppressing a patient's entire immune system. Methods include localized release of immunosuppressive (ISV) agents are contemplated in one embodiment. Methods also include localized application of immunosuppressive (ISV) regulatory T-cells (Tregs) and / or mesenchymal stomal cells in other embodiments. Hydrogel carrier materials are also described herein.

Disclosed herein are methods for sequencing, comprising, providing a sample, wherein the sample comprises a plurality of nucleic acid (NA) molecules, isolating the plurality of NA molecules from the sample, amplifying the plurality of NA molecules, subjecting the plurality of NA molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing the plurality of cDNA molecules or derivatives thereof. Also disclosed herein are systems, comprising a processor and a non-transitory computer readable storage medium encoded with a computer program that causes the processor to provide a sample, wherein the sample comprises a plurality of NA molecules, isolating the plurality of NA molecules from the sample, amplifying the plurality of NA molecules, subjecting the plurality of nucleic acid molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing the plurality of cDNA molecules or derivatives thereof.

Disclosed are compositions and methods for preventing graft versus host disease (GVHD) or allograft rejection in subjects receiving donor cells. Also disclosed are methods enhancing regulatory T (Treg) cells for use in preventing GVHD. Also disclosed are methods of suppressing alloreactive donor cells in a subject receiving transplant donor cells that involves adoptive transfer of the treated Treg cells. Also disclosed are enhanced Treg cells produced by the disclosed methods that have been engineered to express chimeric antigen receptor (CAR) polypeptide cells.

The present invention relates to a prognostic method for determining a probability of allograft rejection using an infrared spectroscopy-based method coupled with a machine learning model. The invention also refers to a method for determining a probability of efficiency of an allograft rejection rescue therapy.

Methods for producing allograft tissue by applying an antimicrobial solution to allograft tissue. The antimicrobial solution exhibits antimicrobial activity to make allograft resistant to microbial organisms, such as bacterium. Surface-modified tissue grafts prepared by these methods are also disclosed.

The present disclosure generally relates to methods of inhibiting an immune response and an immune response involved in transplant rejection, such as an allograft transplant rejection. In particular, the invention relates to the use of specific enzyme inhibitors that can be used to treat transplant rejection and / or prolong the survival of transplanted tissue or organs, in particular allotransplanted tissue or organs.

The present disclosure relates to products and methods for crossmatching transplant donors and recipients. Products and methods provided are based on solid phase supports coated with transplant donor cell membrane fragments. The products and methods are useful in allotransplantation and xenotransplantation.

The present application relates to a bi-functional therapeutic for treating cancer that includes a targeting component which targets a tumor-associated antigen and an enzyme which, when delivered to a tumor by said targeting component, converts the tumor phenotype to that of an incompatible allograft or xenograft. The enzyme is coupled to the targeting component. Also disclosed is a method for treating cancer comprising administering the bi-functional therapeutic.

Disclosed herein are methods for sequencing, comprising, providing a sample, wherein said sample comprises a plurality of nucleic acid (NA) molecules, isolating said plurality of NA molecules from said sample, amplifying said plurality of NA molecules, subjecting said plurality of NA molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing said plurality of cDNA molecules or derivatives thereof. Also disclosed herein are systems, comprising, a processor, and a non-transitory computer readable storage medium encoded with a computer program that causes said processor to providing a sample, wherein said sample comprises a plurality of NA molecules, isolating said plurality of NA molecules from said sample, amplifying said plurality of NA molecules, subjecting said plurality of nucleic acid molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing said plurality of cDNA molecules or derivatives thereof.

Disclosed herein are methods for sequencing, comprising, providing a sample, wherein said sample comprises a plurality of nucleic acid (NA) molecules, isolating said plurality of NA molecules from said sample, amplifying said plurality of NA molecules, subjecting said plurality of NA molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing said plurality of cDNA molecules or derivatives thereof. Also disclosed herein are systems, comprising, a processor, and a non-transitory computer readable storage medium encoded with a computer program that causes said processor to providing a sample, wherein said sample comprises a plurality of NA molecules, isolating said plurality of NA molecules from said sample, amplifying said plurality of NA molecules, subjecting said plurality of nucleic acid molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing said plurality of cDNA molecules or derivatives thereof.

The present disclosure relates to methods of treating or reducing the risk of transplant rejection or increasing a duration of time before transplant rejection occurs in a subject in need thereof (e.g., a human) by administering an antagonist that targets CD40 or CD154, such as an anti-CD40 antibody or an antigen-binding fragment thereof (e.g., a humanized anti-CD40 antibody or antigen-binding fragment thereof. The transplant may be an allogeneic or xenogeneic transplant (e.g., a cell, tissue, or organ or portion thereof).

There is disclosed a system and methods for safely and securely gripping osseous-based tissue during allograft processing. One embodiment includes a first forceps half pivotally coupled to a second forceps half, where the first and the second forceps halves combine to form a handle portion and a head portion. The handle portion may define a first longitudinal axis, and the head portion may define a second longitudinal axis that intersects the first longitudinal axis at a varying head angle. The first and the second halves move between an open position in which the first and second forceps halves at the head portion are separated and a closed position in which the first and second forceps halves at the head portion are together. The forceps may also include an open-biasing spring element attached between the first and second forceps halves and a selective locking mechanism. Other embodiments are also disclosed.

There is disclosed a system and methods for safely and securely gripping osseous-based tissue during allograft processing. One embodiment includes a first forceps half pivotally coupled to a second forceps half, where the first and the second forceps halves combine to form a handle portion and a head portion. The handle portion may define a first longitudinal axis, and the head portion may define a second longitudinal axis that intersects the first longitudinal axis at a varying head angle. The first and the second halves move between an open position in which the first and second forceps halves at the head portion are separated and a closed position in which the first and second forceps halves at the head portion are together. The forceps may also include an open-biasing spring element attached between the first and second forceps halves and a selective locking mechanism. Other embodiments are also disclosed.

Provided are a composition and method for allogeneic transplantation. Provided is an sgRNA combination targeting HLA class I genes, which can knock out HLA-A and HLA-B with high efficiency, and knock out HLA-C with low efficiency. The sgRNA combination can be used for preparing engineered cells with modified HLA class I genes, and the obtained engineered cells can be further used in the prevention and / or treatment of diseases such as cancer, infection or autoimmune diseases.

Methods of reducing allograft rejection or the risk of allograft rejection in a subject are described. The methods include metabolically labelling an allograft tissue or organ with a chemical tag (such as dinitrophenyl), transplanting the labelled tissue or organ, and administering to the transplant recipient T regulatory (Treg) cells expressing a chimeric antigen receptor (CAR) specific for the chemical tag. The CAR-expressing Treg cells are stimulated upon binding to the chemical tag displayed on the transplanted tissue or organ, leading to activation of the Treg cells and suppression of effector CD8+ T cells, thereby generating of an immunosuppressive tissue environment that reduces the risk of allograft rejection. Kits that include a chemical tag, engineered CAR Treg cells specific for the chemical tag, and / or a viral vector encoding a CAR specific for the chemical tag are also described.

The invention discloses a nano self-assembly body capable of reducing allograft rejection. The nano self-assembly body is a nano particle obtained by self-assembling an artesunate-mycophenolic acid ester self-assembly body prodrug and DSPE-PEG2000, wherein the artesunate-mycophenolic acid ester self-assembly body prodrug and the DSPE-PEG2000 are of the following structure. The invention also discloses a preparation method and application of the nano self-assembly body. In addition, the invention also discloses a structure and a preparation method of the artesunate-mycophenolate self-assembly prodrug. In the preparation process of the nano self-assembly, artesunate and mycophenolic acid ester are synthesized into a prodrug through esterification reaction, and then the prodrug is combined with DSPE-PEG2000 to prepare the nano drug. The nano-drug has the characteristic of accurately targeting the spleen, and can effectively remodel the immune microenvironment after transplantation. Through research and development of the nano-drug, the problem of toxic and side effects caused by long-term use of a traditional immunosuppressor and the problem of poor treatment effect of a natural small-molecule immunosuppressor are successfully solved, and the nano-drug shows extremely wide development prospects and huge potential in the field of future clinical application.

The present invention relates to methods for monitoring potential indications of allogeneic organ rejection by monitoring transplanted hair follicles from the same donor of a transplanted organ, and for performing or modifying immunosuppressive therapy to ameliorate or prevent the occurrence of acute or chronic organ rejection. The methods of the invention may also be used to select candidate allogeneic solid organ donors for recipients, as well as to improve the occurrence of acute rejection of transplanted allogeneic solid organs, such as kidneys.

Provided is a method for reducing or eliminating allograft rejection by using a thymus vaccine. The method comprises the following steps: expressing major histocompatibility complex (MHC) from a donor and / or grafting a thymus epithelial cell from a donor in the thymus tissue of a recipient by means of the thymus vaccine. The thymus vaccine includes a thymic gene vaccine and / or a thymocyte vaccine. The thymic gene vaccine is used for expressing an MHC antigen from the donor in the thymus of the recipient, and comprises: (1) a gene expression vector; and (2) polynucleotides separately encoding MHC class I molecules and MHC class II molecules of the donor. The thymocyte vaccine is prepared by the following steps: sorting by using an anti-Epcam antibody to give thymus epithelial cells. By establishing a convenient donor source, the limitations of allograft caused by MHC mismatch are overcome, thus helping solve the clinical problem of limited donor sources.

The invention discloses an allograft cornea stroma lens as well as a preparation method and application thereof, and relates to the technical field of cornea transplantation. The preparation method comprises the following steps: obtaining a corneal stroma lens material from a donor; the cornea stroma lens material is subjected to irradiation and high-low water pressure circulation cleaning, and a semi-finished cornea stroma lens product is obtained; performing low-temperature cryopreservation in sterile glycerol; selecting a proper semi-finished product of the cornea stroma lens, and refrigerating the semi-finished product of the cornea stroma lens at low temperature and rewarming; and soaking the reheated semi-finished cornea stroma lens product in separated platelet-rich serum, so that the platelet-rich serum is adsorbed on the surface of the semi-finished cornea stroma lens product to obtain the allograft cornea stroma lens. Clinical practice observation shows that the curative effect of the cornea stroma lens treated by the process on treatment of intractable macular pores is superior to that of similar surgical treatment using biological amnions. The vision retention of the patient after the operation by using the corneal stroma lens is higher than that after the operation by using the biological amniotic membrane.

Embodiments described herein relate to restorative solutions for segmental peripheral nerve (PN) defects using allografted PNs for stimulating PN repair. More specifically, embodiments described herein provide for localized immunosuppression (LIS) surrounding PN allografts as an alternative to systemically suppressing a patient's entire immune system. Methods include localized release of immunosuppressive (ISV) agents are contemplated in one embodiment. Methods also include localized application of immunosuppressive (ISV) regulatory T-cells (Tregs) and / or mesenchymal stomal cells in other embodiments. Hydrogel carrier materials are also described herein.

The invention provides agonistic TNFR2 antibodies and antigen-binding fragments thereof and encompasses the use of these antibodies as therapeutics to promote the proliferation of regulatory T cells (T-reg) for the treatment of immunological diseases. Antibodies of the invention can be used to potentiate the T-reg-mediated deactivation of self- and allergen-reactive T- and B-lymphocytes, and can thus be used to treat a wide variety of indications, including autoimmune diseases, allergic reactions, asthma, graft-versus-host disease, and allograft rejection, among others.

The present disclosure provides a gel composition comprising: a porous scaffold and a gel coating. The porous scaffold is filled with a biological tissue or a biological cell, and the gel coating covers the porous scaffold. The present disclosure further provides the manufacturing method and the use of the foregoing gel composition, especially the use as an implant for xenotransplantation or allotransplantation.